Joshua D. Fox



Joshua Fox is a leading corporate attorney representing companies in various stages of their lifecycle, from startups to established corporations, with particular emphasis on life sciences and other emerging technology companies, including software, internet and hardware companies. Since joining the firm in 2001, Mr. Fox has counseled numerous entrepreneurs and companies, from prior to the formation of a business entity through an exit event, and regularly advises clients on seed-stage, venture capital, strategic and other financings. He also advises clients in various other transactions, including mergers and acquisitions and public offerings.

Mr. Fox provides advice to companies with respect to incorporation and startup, angel and venture capital financings, mergers and acquisitions, public offerings, securities law compliance and general corporate matters. As a member of the Emerging Company and Venture Capital Practice, Mr. Fox focuses on the representation of early-stage companies, counseling entrepreneurs on the formation of their businesses and serving as counsel to those businesses, including in their initial public offerings and their acquisitions by other corporations. Learn more about Mr. Fox's practice and how he can support your startup on


Public Offerings and PIPE Transactions

  • Aileron Therapeutics, Inc. in its initial public offering 
  • ConforMIS, Inc. in its initial public offering
  • Karyopharm Therapeutics Inc. in its initial public offering
  • AVEO Pharmaceuticals, Inc. in its initial public offering, its private placement of common stock in November 2010, and its private placement of common stock to Johnson & Johnson Development Corporation
  • Infinity Pharmaceuticals, Inc. in its public offering of common stock in December 2012
  • Alnylam Pharmaceuticals, Inc. in its initial public offering

Mergers and Acquisitions

  • Orbitera, Inc. in its sale to Google
  • Aciex Therapeutics, Inc. in its sale to Nicox S.A.
  • Aegis Lightwave, Inc. in its sale to II-VI Incorporated, and its previous acquisitions of CardinalPoint Optics, Inc. and AOFR Pty Limited
  • Infinity Pharmaceuticals, Inc. in its reverse merger with Discovery Partners International, Inc.
  • SkyPhrase in its sale to Yahoo
  • AccuRev in its sale to Micro Focus
  • Axiom Global Inc. in its acquisition of LawyerLink

Venture Capital and Other Financings

  • Suono Bio, Inc.
  • Aquinnah Pharmaceuticals, Inc. 
  • Asimov Inc.
  • Hydra Biosciences, Inc.
  • Karyopharm Therapeutics Inc. (prior to it becoming a public company)
  • AVEO Pharmaceuticals, Inc. (prior to it becoming a public company)
  • Infinity Pharmaceuticals, Inc. (prior to it becoming a public company)
  • Casa Systems, Inc. (prior to it becoming a public company)
  • Aciex Therapeutics, Inc. (prior to its sale)
  • Aegis Lightwave, Inc. (prior to its sale)

Honors & Awards

  • Recommended in the 2016 edition of The Legal 500 United States for finance: capital markets: equity offerings: advice to managers
  • Named a "New England Super Lawyers Rising Star" in corporate law in the 2008, 2010-2016 issues of Boston Magazine
  • Civil Rights Recognition Award Recipient from the Lawyers' Committee for Civil Rights Under Law of the Boston Bar Association (2010)


  • "Standardized Term Sheets May Not Protect Your Interests," Law360 (April 6, 2018)
  • "When to Let Your Competitors Be Your Investors," VentureBeat (September 16, 2017)
  • "Startup M&A: Why a Letter of Intent Deserves Your Full Attention," Xconomy (June 28, 2016)
  • "Five Things You Should Know About Founder Stock Vesting," WilmerHale Launch Blog (October 5, 2015)
  • "When Should Your Biosciences Startup Use an NDA?" NYC Tech Connect and the EIR for NYC Blog (November 13, 2012)
  • "Mistakes Made By Founders of Startup Companies: Advice To Entrepreneurs," Entrepreneurship@BU Newsletter (November 2012)
  • "Founders Stock, Part 1," NYC Tech Connect and the EIR for NYC blog (June 5, 2012)
  • "When Should My Bioscience Startup Move Out of the Academic Lab?" NYC Tech Connect and the EIR for NYC blog (March 13, 2012)
  • "When Should I Incorporate My Bioscience Startup?" NYC Tech Connect and the EIR for NYC blog (February 1, 2012)
  • "Attorneys' View: Tips On Bringing In VC funds," Mass High Tech (May 1, 2009)
  • "Convertible Debt Financing Is A Key Fund-Raising Tool," Boston Business Journal, Banking/Financial Services Quarterly (September 12- 18, 2008)
  • "Don't Overvalue Pre-Money Valuations," TieCon East Conference Publication (June 2007)
  • "Don't Overvalue Premoney Valuations on Term Sheets," Mass High Tech (March 2, 2007)

Speaking Engagements

Mr. Fox is a frequent guest lecturer on a variety of topics.

  • Life Sciences Investment & Market Insights Panel – ArcPoint Strategy, June 6, 2018
  • Starting a Company: Key Issues to Consider – Boston Bar Association, May 9, 2018
  • Your First Financing: Planning for a Successful Fundraising – ELabNYC Webinar, March 28, 2018
  • First Round Investments in Bioscience Ventures – Accelerator for Biosciences Connecticut Roundtable, March 22, 2018
  • The Path to Partnership Part II – ELabNYC Alumni Event – Alexandria LaunchLabs, January 31, 2018
  • Financings: What Entrepreneurs Need to Know – Harvard University – Venture Capital Course, December 7, 2017
  • Financing Your Startup – Tufts University – Entrepreneurial Finance, November 13, 2017
  • Financings: What Entrepreneurs Need to Know – Harvard University – Private Equity Course, July 25, 2017
  • Hiring Your First Employees and Advisors and Letting Them Go When Necessary – WilmerHale QuickLaunch University Webinar, July 20, 2017
  • Building the Legal Infrastructure – Tufts Entrepreneurial Leadership Program – Tufts University, March 4, 2017
  • Venture Capital in Asia – Harvard Business School – 2017 Asia Business Conference, March 4, 2017
  • Financing a Startup – Broad Institute of MIT and Harvard – Biomedical Entrepreneurship Course, January 26, 2017
  • Best Practices for Building a Board of Directors and Board of Advisors – WilmerHale QuickLaunch University: Successfully Launching Your Startup, September 13, 2016
  • Entrepreneurship, Investment and the Greater Good – 2016 Harvard Law Entrepreneurship Project Conference – Harvard Law School, April 9, 2016
  • Knowing Your Exits – Harvard iLab, August 12, 2015  
  • Financing Deal Structures and Term Sheets: Advice to Entrepreneurs – Healthbox, April 16, 2015
  • Launch Smart Clinic – MIT Enterprise Forum, April 2, 2015 
  • One size does not fit all – Financing in the Health and Sciences Market – Harvard iLab, December 4, 2014
  • Intellectual Property and Your Startup Company – Northeastern University IDEA Lab, January 30, 2014

Publications & News


April 6, 2018

Standardized Term Sheets May Not Protect Your Interests

An article by Joshua Fox, published by Law360, focusing on standardized term sheets and how they may inadvertently gloss over or neglect issues that can be critical to founders' long-term success.

January 8, 2018

Five WilmerHale Clients Among PULSE@MassChallenge 2018 Cohort of Top Digital Health Startups

WilmerHale is proud to have five startup clients named to the list of digital health startups joining the 2018 PULSE@MassChallenge cohort. These clients were selected from more than 500 applicants from around the world.

December 22, 2017

WilmerHale Represents Asimov in $4.7 Million Financing

WilmerHale represented Asimov in its recently announced $4.7 million round of funding. The company provides an industry-grade computer-aided design and genetic engineering framework for programming living cells.

October 3, 2017

WilmerHale Counsels Suono Bio in Seed Funding Led by Polaris and MIT’s The Engine

Suono Bio, a company developing a platform technology designed to enable ultra-rapid delivery of therapeutics—including proteins and nucleic acids—to the gastrointestinal tract, has announced that it has raised its seed funding round from Polaris, MIT's “The Engine” and other investors.

September 16, 2017

When to Let Your Competitors Be Your Investors

Partner Joshua Fox, in this guest article published by VentureBeat, discusses the benefits and risks of entrepreneurs seeking capital from competitors, also known as “strategic investors.”

July 6, 2017

WilmerHale Represents Aileron Therapeutics in IPO

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering.

April 25, 2017

WilmerHale Counsels Aquinnah Pharmaceuticals in $10M Investment From Pfizer and AbbVie

Aquinnah Pharmaceuticals announced that Pfizer Inc. and AbbVie Inc. have invested in their work to treat Amyotrophic Lateral Sclerosis, Alzheimer's disease and other neurodegenerative diseases.

September 22, 2016

Matchmaker, Matchmaker, Find Me A Lawyer

Partner Josh Fox is quoted by To Market in this September 2016 article discussing Legal Food Hub's initiative to pair farmers and food entrepreneurs with volunteer attorneys.

August 10, 2016

WilmerHale Advises Orbitera in Acquisition by Google

The Google Cloud Platform team shares Orbitera's vision for seamless purchase and deployment of IT services across heterogeneous cloud infrastructure.

June 22, 2016

The Legal 500 United States 2016 Recognizes 111 WilmerHale Lawyers Across 30 Practice Areas

The guide's rankings are based on a series of criteria, including client feedback, interviews with private practice lawyers, and its own research.

Professional Activities

  • WilmerHale's Hiring Committee, Member
  • WilmerHale's Pro Bono and Community Service Committee, Member
  • WilmerHale's Boston Office Summer Program, Co-Chair (Past)
  • Life Sciences Alliance of the Greater Boston Chamber of Commerce, Member
  • Northeastern University D'Amore-McKim School of Business Board of Visitors, Member

Community Involvement

  • BUILD, Mentor
  • Dana-Farber Cancer Institute Leadership Council, Member 
  • Tufts University Alumni Council, Executive Committee Member
  • Tufts Lawyers Association Board of Directors, Past Member
  • Tufts Lawyers Association, Past President


Skip Navigation Links.


JD, Harvard Law School, 2001

BA, Political Science, summa cum laude, Tufts University, 1998, Phi Beta Kappa

Bar Admissions


New York

Skip Navigation Links.